Paper Details

  1. Home
  2. Paper Details

The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.

Author: EdwardsL, PeetsE, PeredniaD, SmilesK A, TannerD J, TaylorE L, TuckerS B

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Interferon alfa-2b is effective in treating basal cell carcinomas but requires multiple injections. This study evaluated a sustained-release protamine zinc chelate interferon alfa-2b formulation. Eighty percent of evaluable tumors treated with three injections and 52% treated with one injection were cured histologically. The sustained-release formulation shows promise as a practical treatment option.
Paper Details　
Original Abstract of the Article :
Intralesional interferon alfa-2b has been proven effective in the treatment of basal cell carcinomas. Because nine injections over a 3-week period have been necessary to produce clinically significant cure rates, a sustained-release protamine zinc chelate interferon formulation has been developed. I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2383027

データ提供：米国国立医学図書館（NLM）

Intraluminal Interferon Alfa-2b for Basal Cell Carcinomas

Treating basal cell carcinomas can be a real challenge. Imagine trying to get rid of pesky sand dunes in a vast desert! This research uses a special sustained-release interferon alfa-2b formula to tackle these stubborn tumors. The study tested two dosing schedules, one with a single injection and the other with weekly injections for three weeks. The results show a significant difference, with 80% of tumors treated with three injections being cured compared to 52% with a single injection. This sustained-release formula looks promising, potentially making it easier to treat basal cell carcinomas without compromising effectiveness.

A New Weapon in the Fight Against Basal Cell Carcinoma

This study highlights the potential of sustained-release interferon alfa-2b as a treatment option for basal cell carcinoma. The results show a clear advantage of the multi-injection approach, suggesting that this strategy could lead to improved cure rates. These findings are a beacon of hope for patients battling this common skin cancer.

The Takeaway for You

While more research is needed, this study indicates that sustained-release interferon alfa-2b could offer a more convenient and effective treatment for basal cell carcinoma. If you're concerned about skin cancer, it's crucial to consult with a dermatologist for early detection and appropriate treatment. Remember, early detection is key to successful treatment!

Dr. Camel's Conclusion

This research offers a promising new avenue for treating basal cell carcinomas, showcasing the benefits of a sustained-release interferon alfa-2b formulation. The results are a testament to the ongoing efforts to find more effective and convenient treatment options for patients. This research could lead to significant improvements in patient outcomes and quality of life.
Date :
  1. Date Completed 1990-09-10
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

2383027

DOI: Digital Object Identifier

2383027

Related Literature

Article Analysis
・Side Effects of interferon alfa-2b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.